In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche, Syrrx develop cancer, diabetes compounds

Executive Summary

Under terms of a three-year deal, F. Hoffmann-La Roche and Syrrx agreed to discover and develop cancer and Type II diabetes drug candidates that act on HDAC (histone deacetylase), a cancer target that regulates gene transcription, and 11-beta HSD-1, a metabolic target that reduces cortisol production. The programs are in the preclinical development stage.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies